SAR439459 is a pan‐TGF‐β antibody that has demonstrated preclinical activity in human cell lines and murine tumor models, in which treatment inhibited the TGF‐β‐induced suppression of CD8+ T cells and the development of Treg cells [42]. This evidence concerns the gene TGFB1 and neoplasm.